文献速递性腺与生殖内分泌垂体与肾上腺疾病

21-羟化酶缺陷女性携带者的辅助生殖技术治疗结局

Assisted Reproduction Technology Treatment Outcomes in Female Carriers of 21-Hydroxylase Deficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本回顾性队列研究纳入1284例受试者的1556个体外受精周期,比较244例CYP21A2致病性变异女性携带者与1040例非携带者的辅助生殖结局。携带者与非携带者的活产率、种植率和临床妊娠率均无显著差异,单变量分析中受精率差异在多变量分析后不再显著,提示携带者体外受精结局与非携带者相当。

要点

  • CYP21A2致病性变异女性携带者与非携带者的活产率、种植率和临床妊娠率均无显著差异。
  • 携带者与非携带者的基线特征和卵巢刺激参数相似。
  • 单变量分析中受精率差异在多变量分析后不再显著(校正OR 1.05;95%CI 0.93-1.18)。

核心结论

  • 携带CYP21A2致病性变异的女性患者体外受精结局与非携带者相当。
  • 这些发现支持对携带者维持标准辅助生殖治疗方案,并有助于为经基因筛查识别的携带者提供个性化咨询。

研究设计与样本

  • 单中心私立学术中心的回顾性队列研究。
  • 最终纳入1284例受试者的1556个体外受精周期,包括244例携带者和1040例非携带者对照。
  • 暴露因素为女性单等位基因CYP21A2突变携带状态。
  • 主要结局指标为冻融单整倍体胚胎移植后的活产率。

主要发现

  • 携带者与非携带者的活产率分别为50.7% vs 51.1%(P=.87),无显著差异。
  • 携带者与非携带者的种植率分别为75.4% vs 73.4%(P=.99),无显著差异。
  • 携带者与非携带者的临床妊娠率分别为63.3% vs 62.7%(P=.73),无显著差异。
  • 单变量分析中受精率携带者81.7% vs 非携带者83.3%(P=.008)显示显著差异,但多变量分析校正混杂变量后该差异未观察到(校正OR 1.05;95%CI 0.93-1.18)。
  • 携带者与非携带者的基线特征和卵巢刺激参数相似。

临床怎么用

  • 作者认为这些发现支持对携带者维持标准辅助生殖治疗方案,并有助于为经基因筛查识别的携带者提供个性化咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Carriers of a CYP21A2 pathogenic variant exhibit distinct hormonal differences, yet their impact on assisted reproductive technology outcomes remains unknown. OBJECTIVE: To evaluate whether carriers of a CYP21A2 pathogenic variant exhibit differences in ovarian stimulation response and in vitro fertilization outcomes compared with noncarriers. DESIGN: A retrospective cohort study at a single, private, academic center. SUBJECTS: A total of 1284 subjects undergoing 1556 in vitro fertilization cycles were ultimately included in the analysis, comprising 244 carriers and 1040 noncarrier controls. EXPOSURE: Female monoallelic CYP21A2 mutation carrier status. MAIN OUTCOME MEASURES: Live birth rates following frozen single euploid embryo transfer. Secondary outcomes included ovarian stimulation parameters, embryological development (fertilization and euploidy rates), and posttransfer outcomes (implantation, clinical pregnancy, and pregnancy loss rates). RESULTS: Baseline characteristics and ovarian stimulation parameters were similar between pathogenic CYP21A2 variant carriers and noncarriers. No significant differences were observed in live birth (50.7% vs 51.1%, P = .87), implantation (75.4% vs 73.4%, P = .99), or clinical pregnancy (63.3% vs 62.7%, P = .73) rates between carriers and noncarriers, respectively. Although a univariate analysis of fertilization rates (81.7% vs 83.3%, P = .008) showed a significance difference, this difference was not observed after adjusting for confounding variables in a multivariate analysis (adjusted odds ratio of 1.05; 95% CI, 0.93-1.18). CONCLUSION: Female patients who carry a pathogenic CYP21A2 variant achieve in vitro fertilization outcomes comparable to noncarriers. These findings support maintaining standard assisted reproductive treatment protocols for carriers and help provide personalized counseling for carriers identified through genetic screening.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Arcaz AC, Hernandez-Nieto C, Lee JA, et al. Assisted Reproduction Technology Treatment Outcomes in Female Carriers of 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2025. PMID: 40171917. doi:10.1210/clinem/dgaf198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。